AzTrials
AzTrials

Type 1 Diabetes MellitusNCT02374879

User Performance and System Accuracy Evaluations Using Glucose Adjustment

A study testing Blood Glucose Monitoring Systems. in people with Type 1 Diabetes Mellitus, run by LifeScan at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is an open-label, non-randomised pilot study, to evaluate user performance and system accuracy in blood Glucose monitoring system with glucose adjustment. Twelve male and female volunteers aged 18-45, with a documented diagnosis of Type I diabetes for at least 12 will be enrolled in this study. Read more about this study

Who is it for?
Ages 18 to 45 years
Conditions the study is for
Type 1 Diabetes Mellitus
What is being tested?
Blood Glucose Monitoring Systems.
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
12 participants
Where
1 siteUnited Kingdom
Study dates
1 Feb 2015to 1 Feb 2015
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • All sexes
  • No healthy volunteers
  • Adult

Summary of inclusion criteria.

  • Male and female volunteers aged 18-45, with a documented diagnosis of Type I diabetes for at least 12 months and treated with a basal bolus insulin regime, and deemed otherwise healthy as determined by medical history, physical examination, laboratory test values, vital signs and 12-lead ECGs at screening.
  • Non-smokers from at least 12 months before study start and for the duration of the study.
  • Body mass index (BMI) ≥ 18 and ≤ 30 kg/m2.
  • Able to voluntarily provide written informed consent to participate in the study.
  • Must understand the purposes and risks of the study and agree to follow the restrictions and schedule of procedures as defined in the protocol, as confirmed during the informed consent process.
  • Must be willing to consent to have data entered into The Over Volunteering Prevention System (TOPS).
  • The volunteer's primary care physician has confirmed within the last 12 months that there is nothing in their medical history that would preclude their enrolment into a clinical study.
  • User Performance Accuracy Testing Only: Self-Monitoring - Volunteer is currently performing unassisted self-monitoring of blood glucose.

Summary of exclusion criteria.

  • A severe hypoglycaemic reaction, defined as causing loss of consciousness and/or requiring outside assistance with oral or intravenous glucose or a glucagon injection, within 7 days of the study start date.
  • Female volunteers who are pregnant or lactating.
  • Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
  • Current or history of drug or alcohol abuse or a positive drugs of abuse or alcohol test at screening or check-in.
  • Participation in a clinical drug study during the 90 days prior to study start.
  • Any clinically significant illness within 30 days prior to study start.
  • Donation of blood or blood products within 30 days prior to study start, or at any time during the study, except as required by this protocol.
  • Weekly alcohol intake exceeding the equivalent of 14 units per week for females or 21 units per week for males.
  • Consumption of alcoholic beverages within 48 hours prior to check-in.
  • Volunteers with a substantial change in eating habits within 30 days prior to study start or volunteers who cannot comply with the standardised meals proposed for use in the study.
  • Prior experience with the BGMSs used for the study.
  • Volunteers who are currently working for, have previously worked for, or have an immediate family member working for a company that manufactures or markets blood glucose monitoring products.
  • Volunteers who have laboratory training or experience (medical technologist, laboratory technician, laboratory assistant etc).
  • Volunteers who, in the opinion of the Investigator, are unsuitable for participation in the study.

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • BioKinetic Europe Ltd

    Belfast, Antrim, BT2 7BA

Other trials in United Kingdom

About this study

This is an open-label, non-randomised pilot study, to evaluate user performance and system accuracy in blood Glucose monitoring system with glucose adjustment. Twelve male and female volunteers aged 18-45, with a documented diagnosis of Type I diabetes for at least 12 will be enrolled in this study.

Being tested
Blood Glucose Monitoring Systems.
Medical subject headings
Diabetes Mellitus, Type 1

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Blood Glucose Monitoring Systems.Device

    In vitro diagnostic medical device.

Study groups in NCT02374879
Study groupRoleWhat they receive
Blood Glucose monitoring System (BGMS)ExperimentalIntervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
Receives: Device: Blood Glucose Monitoring Systems.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. User Performance (UP) evaluation.

    UP evaluation of blood glucose monitoring systems compared to a reference instrument. Samples collected by subject and HCP

    Measured: Up to 6 hours

  2. System Accuracy (SA) evaluation

    UP evaluation of blood glucose monitoring systems compared to a reference instrument. Samples collected by HCP only.

    Measured: Up to 6 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Mar 2015 (estimated)
  2. Study start1 Feb 2015
  3. Primary completion1 Feb 2015
  4. Study completion1 Feb 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
12 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02374879
Sponsor's protocol ID
3128466
Status last verified
Aug 2017
First submitted
18 Feb 2015
Last updated
16 Aug 2017
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Blood Glucose Monitoring Systems. in people with Type 1 Diabetes Mellitus, run by LifeScan at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

User Performance (UP) evaluation. (time frame: Up to 6 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Aug 2017.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in